Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial
Table 2
Incidence of adverse events.
VPZ group ()
PPI group ()
value VPZ versus PPI
RPZ group ()
value VPZ versus RPZ
Overall
19 (26.3%)
26 (37.7%)
0.1505
20 (33.9%)
0.3497
Loose stool
12 (16.6%)
12 (17.4%)
0.9089
9 (15.3%)
0.8265
Diarrhea
6 (8.3%)
10 (14.5%)
0.2490
8 (13.6%)
0.3354
Dysgeusia
3 (4.1%)
6 (8.7%)
0.3192
5 (8.5%)
0.4664
Skin eruption
1 (1.4%)
3 (4.3%)
0.3591
2 (3.4%)
0.5881
Abdominal bloating
1 (1.4%)
2 (2.9%)
0.6143
1 (1.7%)
1.0000
Epigastralgia
0 (0%)
2 (2.9%)
0.2377
2 (3.4%)
0.4504
Constipation
1 (1.4%)
1 (1.4%)
1.0000
1 (1.7%)
1.0000
Nausea
1 (1.4%)
1 (1.4%)
1.0000
1 (1.7%)
1.0000
Others
2 (2.8%)
4 (5.8%)
0.4348
3 (5.1%)
0.6571
Data are expressed as number (percentage). Statistical analyses were conducted with the chi-square test or Fisher’s exact test. VPZ group, treatment with vonoprazan, amoxicillin, and clarithromycin; PPI group, treatment with rabeprazole or lansoprazole, amoxicillin, and clarithromycin; RPZ group, treatment with rabeprazole, amoxicillin, and clarithromycin.
